Putensen, C. and Ellger, B. and Sakka, S. G. and Weyland, A. and Schmidt, K. and Zoller, M. and Weiler, N. and Kindgen-Milles, D. and Jaschinski, U. and Weile, J. and Lindau, S. and Kieninger, M. and Faltlhauser, A. and Jung, N. and Teschendorf, P. and Adamzik, M. and Gruendling, M. and Wahlers, T. and Gerlach, H. and Litty, F. -A. (2019) Current clinical use of intravenous fosfomycin in ICU patients in two European countries. INFECTION, 47 (5). pp. 827-836. ISSN 0300-8126, 1439-0973
Full text not available from this repository. (Request a copy)Abstract
Purpose In Europe, intravenous fosfomycin (IV) is used particularly in difficult-to- treat or complex infections, caused by both Gram-positive and Gram-negative pathogens including multidrug-resistant strains. Here, we investigated the efficacy and safety of intravenous fosfomycin under real-life conditions. Methods Prospective, multi-center, and non-interventional study in patients with bacterial infections from 20 intensive care units (ICU) in Germany and Austria (NCT01173575). Results Overall, 209 patients were included (77 females, 132 males, mean age: 59 +/- 16 years), 194 of which were treated in intensive care (APACHE II score at the beginning of fosfomycin therapy: 23 +/- 8). Main indications (+/- bacteremia or sepsis) were infections of the CNS (21.5%), community- (CAP) and hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP, 15.3%), bone and joint infections (BJI, 11%), abdominal infections (11%), and bacteremia (10.5%). Most frequently identified pathogens were S. aureus (22.3%), S. epidermidis (14.2%), Enterococcus spp. (10.8%), E. coli (12.3%) and Klebsiella spp. (7.7%). At least one multidrug-resistant (MDR) pathogen was isolated from 51 patients (24.4%). Fosfomycin was administered with an average daily dose of 13.7 +/- 3.5 g over 12.4 +/- 8.6 days, almost exclusively (99%) in combination with other antibiotics. The overall clinical success was favorable in 81.3% (148/182) of cases, and in 84.8% (39/46) of patients with >= 1 MDR pathogen. Noteworthy, 16.3% (34/209) of patients developed at least one, in the majority of cases non-serious, adverse drug reaction during fosfomycin therapy. Conclusion Our data suggest that IV fosfomycin is an effective and safe combination partner for the treatment of a broad spectrum of severe bacterial infections in critically ill patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INTENSIVE-CARE-UNIT; MULTIDRUG-RESISTANT; CEREBROSPINAL-FLUID; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; KLEBSIELLA-PNEUMONIAE; INFECTIONS; CARBAPENEMS; TIGECYCLINE; EFFICACY; Intravenous fosfomycin; Non-interventional study; Intensive care; Gram-positive; Gram-negative; Multidrug resistance |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Anästhesiologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Mar 2020 05:30 |
| Last Modified: | 26 Mar 2020 05:30 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26036 |
Actions (login required)
 |
View Item |
